Effect of visco-less single-incision ICL implantation for myopic eyes

Session Details

Session Title: Posterior Chamber Phakic IOLs

Session Date/Time: Sunday 15/09/2019 | 14:00-16:00

Paper Time: 14:24

Venue: Free Paper Forum: Podium 3

First Author: : L.Liu CHINA

Co Author(s): :    J. Li                             

Abstract Details

Purpose:

Retained viscoelastic is a main cause of elevated intraocular pressure after ICL (Visian ICL V4c) implantation. This research was aimed to study the effect of viscoless single-incision ICL implantation for myopic eyes.

Setting:

Refractive Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology

Methods:

In this study, 104 patients were randomly assigned to viscoless group and control group to undergo ICL implantation using a random number Table. In viscoless group, viscoelastic was infused after the ICL injection into anterior chamber. In control group, viscoelastic was used both before and after injection of the ICL. Incidence of immediate ocular hypertension, corneal endothelial changes (endothelial cell density, ECD; coefficient of variation in cell size, CV; percentage of hexagonal cells, HEX), and lens transparency after surgery were compared between the two groups.

Results:

All the surgeries were uneventful. No difference was found in visual outcome between the two groups. The incidences of immediate ocular hypertension attributed to retained viscoelastic were 3.85 % and 13.46 % in viscoless group and control group respectively (P < 0.05). One month after surgery, the mean central ECD losses were 0.54 % and 0.51% in viscoless group and control group respectively (P > 0.05). Up to one year after surgery, there was no significant change in central ECD, CV or HEX either group. By the last postoperative visit, no eye with lens opacity had been found.

Conclusions:

The study concluded that viscoless single-incision ICL (V4c model) implantation is a safe procedure with lower incidence of ocular hypertension in the immediate postoperative period.

Financial Disclosure:

receives non monetary benefits from a company producing, developing or supplying the product or procedure presented, receives non monetary benefits from a competing company